HIV-1 is not yet curable for the vast majority of people living with the virus. Only a handful of individuals have ever been fully cured, all through a risky cancer treatment that isn’t practical as a general approach. However, modern antiretroviral therapy (ART) can suppress the virus so effectively that people diagnosed and treated early now live into their 70s and 80s, only a few years short of the general population’s life expectancy. Several experimental strategies are working toward a true cure, but none is ready for widespread use.
What “Cured” Actually Means for HIV
Researchers define an HIV cure in two ways. A sterilizing cure means every copy of the virus capable of replicating has been completely eliminated from the body. A functional cure means the virus is still present but the immune system controls it indefinitely without medication, keeping viral levels undetectable and immune cell counts normal.
The distinction matters because HIV doesn’t just float around in the bloodstream. It stitches its genetic code directly into immune cells, creating what scientists call a latent reservoir. These infected cells can sit quietly for years or decades, invisible to both the immune system and medications. The moment ART stops, the reservoir wakes up and the virus rebounds, usually within weeks. This reservoir is the central reason HIV is so difficult to cure.
Where HIV Hides in the Body
The virus primarily infects CD4 T cells, a type of white blood cell that coordinates immune responses. Among these, central memory T cells are considered the most important hiding spot. These cells are long-lived by design, meant to “remember” past infections for years, which makes them an ideal vault for dormant HIV.
Beyond T cells, macrophages (immune cells found in nearly every organ) may also harbor the virus, though their role as a reservoir is still debated. Specialized versions of macrophages in the liver, lungs, intestines, and brain could each shelter HIV independently. Even follicular dendritic cells in lymph nodes can carry infectious virus particles on their surface without being infected themselves.
Anatomically, HIV-infected cells have been found in the brain, cerebrospinal fluid, lungs, kidneys, liver, fat tissue, gastrointestinal tract, reproductive organs, and bone marrow. Lymphoid tissues like the spleen, thymus, and gut-associated lymphoid tissue are the most significant sites. HIV DNA can still be detected in lymph nodes after years of successful treatment. This widespread distribution means any cure strategy must reach virtually every tissue in the body.
The People Who Have Been Cured
The first person cured of HIV, widely known as the Berlin Patient, received a stem cell transplant in 2007 to treat acute myeloid leukemia. His doctors deliberately selected a donor with two copies of a rare genetic mutation called CCR5-delta32. HIV typically enters cells by latching onto a surface protein called CCR5. People born with two copies of the delta32 mutation produce a nonfunctional version of that protein, making their cells highly resistant to HIV infection. After the transplant replaced his immune system with donor cells, the Berlin Patient stopped antiretroviral therapy and showed no viral rebound. He remained HIV-free until his death from cancer in 2020.
A small number of other patients have since been cured through similar transplants, including the London Patient and the Düsseldorf Patient. But stem cell transplantation carries serious risks, including graft-versus-host disease and a mortality rate that makes it unjustifiable for someone whose HIV is well-controlled on medication. Every person cured this way needed the transplant for a life-threatening blood cancer, not for HIV itself. The procedure also requires finding a compatible donor with the rare CCR5-delta32 mutation, found almost exclusively in people of Northern European descent.
These cases proved that a sterilizing cure is biologically possible. They also revealed a potential blueprint: if you can make immune cells resistant to HIV entry, the virus loses its ability to sustain itself.
Experimental Cure Strategies
Two broad approaches dominate current research. The first, called “shock and kill,” aims to flush HIV out of its hiding places and then destroy the newly exposed infected cells. Latency-reversing agents force dormant virus to start producing viral proteins, which flags the cell for destruction by the immune system or by targeted drugs. Early clinical testing of several such agents has shown they can activate some latent virus, but not enough to meaningfully shrink the reservoir on their own.
The second approach, “block and lock,” takes the opposite tactic. Instead of waking the virus up, it tries to silence it so deeply that it can never reactivate, even without ART. The most advanced compound in this category works by blocking a key viral protein that HIV needs to copy itself, while also triggering chemical changes around the viral DNA that keep it tightly locked down. This strategy wouldn’t eliminate HIV from the body, but it could achieve a functional cure if the silencing proves durable enough.
Gene Editing
CRISPR-based gene therapy represents one of the most direct approaches. A therapy called EBT-101 is designed to be delivered as a single dose, using gene-editing tools to physically cut the HIV genetic code out of infected cells. It entered Phase 1 clinical testing to assess safety, how widely it distributes through the body, and whether it can successfully excise latent viral DNA. Results from this early-stage trial will determine whether the approach is safe enough to test further, but it remains years away from any potential approval.
Broadly Neutralizing Antibodies
Some people with HIV naturally produce rare, powerful antibodies capable of neutralizing many different strains of the virus. Researchers have been testing whether giving these antibodies to patients could let them stop ART without viral rebound. In one study of children who started ART very early, a combination of two such antibodies kept 44% of participants at undetectable viral levels through 24 weeks without any other HIV medication. That’s a meaningful signal. But in adults who acquired HIV later, a single antibody called VRC01 showed no significant advantage over placebo in preventing viral rebound after stopping ART. The timing of treatment, the number of antibodies used, and individual viral characteristics all seem to influence whether this approach works.
mRNA Vaccines
Building on the technology behind COVID-19 vaccines, the NIH has launched clinical trials of mRNA-based HIV vaccines designed to train the immune system to recognize the spike protein HIV uses to enter cells. These are preventive vaccines, not therapeutic ones aimed at curing existing infections. But the platform could eventually inform therapeutic vaccine strategies as well. The first trials are enrolling adults to test safety and immune response, not efficacy against infection.
Life Expectancy With Treatment
While a cure remains out of reach, the practical reality of living with HIV has transformed. A 20-year-old starting ART today can expect to live into their mid-to-late 70s based on cohort data from Europe and North America. For a 40-year-old man starting modern ART, estimated remaining life expectancy is about 37 years, compared to roughly 41 years in the general population. For a 40-year-old woman, it’s about 39 years compared to nearly 46 in the general population.
The gap narrows further for people who begin treatment with strong immune function. Those who started ART with high CD4 cell counts had life expectancies within just a couple of years of their HIV-negative peers. Starting treatment early, before the virus has time to damage the immune system, is the single most impactful factor.
Globally, progress on treatment access is significant but uneven. As of 2023, roughly 86% of people living with HIV worldwide knew their status, 89% of those were on treatment, and 93% of those on treatment had achieved viral suppression. Men lag behind women on testing and treatment uptake, with 83% aware of their status compared to 91% of women.
Why a Cure Is Taking So Long
The latent reservoir is the core obstacle, but it’s not the only one. Clinical trials for cure strategies face unique ethical challenges. Testing whether a new treatment actually works often requires participants to stop ART entirely, which carries a real risk of viral rebound and potential transmission. Researchers must weigh this carefully, and participants need to understand that “cure research” at this stage means safety testing, not a likely personal benefit.
There’s also the sheer biology of the problem. HIV’s reservoir is scattered across dozens of tissue types throughout the body. Gene-editing tools need to reach cells in the brain, gut, and lymph nodes simultaneously. Immune-based strategies need to overcome HIV’s extraordinary ability to mutate and evade antibodies. And any scalable cure must work for millions of people with different viral strains, immune histories, and genetic backgrounds, not just the rare individual who happens to need a stem cell transplant from a donor with a specific mutation.
The handful of confirmed cures prove the virus can be beaten. The challenge now is finding a way to replicate that outcome safely, affordably, and at scale.